A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day.

IF 2.7 3区医学 Q2 PSYCHIATRY

Journal of Attention Disorders Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI:10.1177/10870547231222260

Lenard A Adler, Deepti Anbarasan, Taylor Sardoff, Terry Leon, Richard Gallagher, Caleb A Massimi, Stephen V Faraone

{"title":"A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day.","authors":"Lenard A Adler, Deepti Anbarasan, Taylor Sardoff, Terry Leon, Richard Gallagher, Caleb A Massimi, Stephen V Faraone","doi":"10.1177/10870547231222260","DOIUrl":null,"url":null,"abstract":"Objective: To examine the effects of triple beaded mixed amphetamine salts (TB MAS) on ADHD and executive dysfunction symptoms throughout the day in adults with DSM-5 ADHD.Method: This was a 6 week, single-blind, placebo-lead in trial of TB MAS (12.5-37.5 mg/day); all participants received 2 weeks of single-blind placebo); one individual was a placebo responder and was discontinued. One of these 18 dropped after 1 week on 12.5 mg/day, while all others completed the trial and received 37.5 mg/day TB MAS.Results: There were significant effects of TB MAS on all clinical measures, including investigator overall symptoms (AISRS); self-report overall (ASRS), time-sensitive ADHD (TASS) scores throughout the day, impairment (CGI) and executive function scores (BRIEF-A). TB MAS was generally well tolerated.Conclusions: This study extends prior findings of TB MAS to adults with DSM-5 ADHD; it further re-validates findings of efficacy of TB MAS throughout the day.","PeriodicalId":15237,"journal":{"name":"Journal of Attention Disorders","volume":" ","pages":"810-819"},"PeriodicalIF":2.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Attention Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10870547231222260","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine the effects of triple beaded mixed amphetamine salts (TB MAS) on ADHD and executive dysfunction symptoms throughout the day in adults with DSM-5 ADHD.

Method: This was a 6 week, single-blind, placebo-lead in trial of TB MAS (12.5-37.5 mg/day); all participants received 2 weeks of single-blind placebo); one individual was a placebo responder and was discontinued. One of these 18 dropped after 1 week on 12.5 mg/day, while all others completed the trial and received 37.5 mg/day TB MAS.

Results: There were significant effects of TB MAS on all clinical measures, including investigator overall symptoms (AISRS); self-report overall (ASRS), time-sensitive ADHD (TASS) scores throughout the day, impairment (CGI) and executive function scores (BRIEF-A). TB MAS was generally well tolerated.

Conclusions: This study extends prior findings of TB MAS to adults with DSM-5 ADHD; it further re-validates findings of efficacy of TB MAS throughout the day.

查看原文本刊更多论文

针对 DSM-5 多动症成人的三珠混合安非他明盐单盲安慰剂对照试验，评估全天效果。

目的研究三珠混合安非他明盐（TB MAS）对患有 DSM-5 多动症（ADHD）的成人全天多动症和执行功能障碍症状的影响：这是一项为期 6 周、单盲、安慰剂引导的 TB MAS（12.5-37.5 毫克/天）试验；所有参与者均接受了为期 2 周的单盲安慰剂治疗）；其中一人对安慰剂有反应，因此停药。这 18 人中有一人在服用 12.5 毫克/天的药物 1 周后停药，其他人都完成了试验并服用了 37.5 毫克/天的 TB MAS：结果：TB MAS 对所有临床指标都有明显效果，包括研究者总体症状（AISRS）、自我报告总体症状（ASRS）、全天时间敏感多动症（TASS）评分、障碍（CGI）和执行功能评分（BRIEF-A）。TB MAS 的耐受性普遍良好：本研究将 TB MAS 之前的研究结果扩展到了患有 DSM-5 多动症的成人；它进一步重新验证了 TB MAS 在全天的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Attention Disorders PSYCHIATRY-

CiteScore

7.60

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Journal of Attention Disorders (JAD) focuses on basic and applied science concerning attention and related functions in children, adolescents, and adults. JAD publishes articles on diagnosis, comorbidity, neuropsychological functioning, psychopharmacology, and psychosocial issues. The journal also addresses practice, policy, and theory, as well as review articles, commentaries, in-depth analyses, empirical research articles, and case presentations or program evaluations.